Editorial: Metabolic therapy in cardiac surgery - "Optimizing the engine's fuel supply and more..."

Scandinavian Cardiovascular Journal

Volumn 44, Issue 1, 2010, Pages 4-8

  Doenst, Torsten ^a   Amorim, Paulo A ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A; ADENOSINE KINASE; ADENOSINE TRIPHOSPHATE; AMINO ACID; CARBOHYDRATE; CARNITINE PALMITOYLTRANSFERASE I; ETOMOXIR; FATTY ACID; GLUCOSE; INSULIN; KETONE BODY; MALONYL COENZYME A DECARBOXYLASE; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; POTASSIUM; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVIC ACID; RANOLAZINE; RESVERATROL; TRIMETAZIDINE; CARDIOPLEGIC AGENT; GLUCOSE INSULIN POTASSIUM CARDIOPLEGIC SOLUTION; GLUCOSE-INSULIN-POTASSIUM CARDIOPLEGIC SOLUTION; GLUTAMIC ACID;

CITRIC ACID CYCLE; EDITORIAL; ENZYME REGULATION; GLUCOSE UTILIZATION; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART SURGERY; HUMAN; INSULIN RESISTANCE; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; RESPIRATORY CHAIN; CONVALESCENCE; CORONARY ARTERY BYPASS GRAFT; ENERGY METABOLISM; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METABOLISM; NOTE; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATE; CARDIOPLEGIC SOLUTIONS; CORONARY ARTERY BYPASS; ENERGY METABOLISM; GLUCOSE; GLUTAMIC ACID; HEART FAILURE; HUMANS; INSULIN; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; POTASSIUM; RECOVERY OF FUNCTION; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 76649129017     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017430903469928     Document Type: Editorial

References (41)

1. Taegtmeyer H. Fueling the heart: Multiple roles for cardiac metabolism. In: Willerson JT, Cohn JN, Wellens HJJ, Holmes DR, editors. Cardiovasc Med, 3rd ed. London: Springer- Verlag (London); 2007. pp. 1157-1175
2. Doenst T, Bugger H, Schwarzer M, Faerber G, Borger MA, Mohr FW. Three good reasons for heart surgeons to understand cardiac metabolism. Eur J Cardiothorac Surg. 2008;33: 862-871
3. Svedjeholm R. A metabolic protective strategy could improve long-term survival in patients with LV-dysfunction undergoing CABG. Scand Cardiovasc J. 2010;44:45-58.
4. Goodwin GW, Taegtmeyer H. Regulation of fatty acid oxidation of the heart by MCD and ACC during contractile stimulation. Am J Physiol. 1999;277(4 Pt 1):E772-77.
5. Taegtmeyer H, Hems R, Krebs HA. Utilization of energyproviding substrates in the isolated working raTheart. Biochem J. 1980;186:701-711
6. Hue L, Taegtmeyer H. The Randle cycle revisited: A new head for an old hat. Am J Physiol Endocrinol Metab. 2009;297:E578-91.
7. Russell RR, Taegtmeyer H. Pyruvate carboxylation prevents the decline in contractile function of raThearts oxidizing acetoacetate. Am J Physiol. 1991;261:H1756-62.
8. Gibala MJ, Young ME, Taegtmeyer H. Anaplerosis of the citric acid cycle: Role in energy metabolism of heart and skeletal muscle. Acta Physiol Scand. 2000;168:657-665
9. Jessen ME, Kovarik TE, Jeffrey FM, Sherry AD, Storey CJ, Chao RY, et al.. Effects of amino acids on substrate selection, anaplerosis, and left ventricular function in the ischemic reperfused raTheart. J Clin Invest. 1993;92:831-839
10. Sambandam N, Lopaschuk GD. AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Progress Lipid Res. 2003;42: 238-256
11. Stanley WC, Sabbah HN. Metabolic therapy for ischemic heart disease: The rationale for inhibition of fatty acid oxidation. Heart Fail Rev. 2005;10:275-279
12. Lopaschuk GD. Optimizing cardiac energy metabolism: How can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis. 2001;12:S8-11.
13. D'Hahan N, Taouil K, Dassouli A, Morel JE. Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6. Eur J Pharmacol. 1997;328:163-174
14. Schwarzer M, Faerber G, Rueckauer T, Blum D, Pytel G, Mohr FW, et al.. The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo. Basic Res Cardiol. 2009;104:547-557
15. Turcani M, Rupp H. Modifi cation of left ventricular hypertrophy by chronic etomixir treatment. Br J Pharmacol. 1999;126:501-507
16. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J. 2001;22:2164-2170
17. Bristow M. Etomoxir: A new approach to treatment of chronic heart failure. Lancet. 2000;356(9242):1621-1622
18. Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R, et al.. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008;57:696-705.
19. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, et al.. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104:403-411
20. Dyck JR, Lopaschuk GD. AMPKalterations in cardiac physiology and pathology: Enemy or ally? J Physiol. 2006; 574:95-112.
21. Taegtmeyer H, Wilson CR, Razeghi P, Sharma S. Metabolic energetics and genetics in the heart. Ann N Y Acad Sci. 2005;1047:208-218
22. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 1997;34:25-33.
23. Gavi S, Hensley J. Diagnosis and management of type 2 diabetes in adults: A review of the ICSI guideline. Geriatrics. 2009;64:12-17, 29.
24. Smith KS. Insulin and glucose in the treatment of heart disease. Brit Med J. 1933;186:693-696
25. Sodi-Pallares D, Bisteni A, Medrano GA, Testelli MR, DeMichell A. The polarizing treatment of acute myocardial infarction. Dis Chest. 1963;43:424-432
26. Lazar HL, McDonnell M, Chipkin SR, Furnary AP, Engelman RM, Sadhu AR, et al.. The Society of Thoracic Surgeons practice guideline series: Blood glucose management during adult cardiac surgery. Ann Thorac Surg. 2009;87:663-669
27. Taegtmeyer H, McNulty PH, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I General concepts. Circulation. 2002;105:1727-1733 (Pubitemid 34298619)
28. Depre C, Vanoverschelde JLJ, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578-588
29. Doenst T, Bothe W, Beyersdorf F. Therapy with insulin in cardiac surgery: Controversies and possible solutions. Ann Thorac Surg. 2003;75:S721-28.
30. Doenst T, Richwine RT, Bray MS, Goodwin GW, Frazier OH, Taegtmeyer H. Insulin improves functional and metabolic recovery of reperfused working raTheart. Ann Thorac Surg. 1999;67:1682-1688
31. Van Den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al.. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367
32. Gandhi GY, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, O'Brien PC, et al.. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: A randomized trial. Ann Intern Med. 2007;146: 233-243
33. Schwarzer M, Schrepper A, Bugger H, Pytel G, Mohr FW, Doenst T. Abstract 5386: The development of heart failure in rats is associated with impaired insulin response and mitochondrial dysfunction. Circulation. 2008;118:540.
34. Amorim P, Nguyen TD, Schrepper A, Mohr FW, Doenst T. Postinfarct remodeling causes insulin resistance and defects in substrate oxidation. Thorac Cardiovasc Surg. 2009; 56(S01):P76.
35. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996;94:2837-2842
36. Neubauer S. The failing heart--an engine out of fuel. N Engl J Med. 2007;356:1140-1151
37. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, et al.. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation. 1992;86:1810-1818
38. Pagel-Langenickel I, Bao J, Joseph JJ, Schwartz DR, Mantell BS, Xu X, et al.. PGC-1alpha integrates insulin signaling, mitochondrial regulation, and bioenergetic function in skeletal muscle. J Biol Chem. 2008;283: 22464-22472
39. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMPactivated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA. 2007;104:12017-12022
40. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem. 2005;280: 17187-17195
41. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: The clinicians' perspective. Heart Fail Rev. 2002;7: 187-203.